Literatur
-
1
Ross R J, Leung K C, Maamra M. et al .
Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.
J Clin Endocrinol Metab.
2001;
86
1716-1723
-
2
Maamra M, Kopchick J J, Strasburger C J, Ross R J.
Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization.
J Clin Endocrinol Metab.
2004;
89
4532-4537
-
3
Gent J, Van Den Eijnden M, Van Kerkhof P, Strous G J.
Dimerization and signal transduction of the growth hormone receptor.
Mol Endocrinol.
2003;
17
967-975
-
4
Kopchick J J, Parkinson C, Stevens E C, Trainer P J.
Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Endocr Rev.
2002;
23
623-646
-
5
van der Lely A J, Hutson R K, Trainer P J. et al .
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
Lancet.
2001;
358
1754-1759
-
6
Holdaway I M, Rajasoorya C R, Gamble G D, Stewart A W.
Long-term treatment outcome in acromegaly.
Growth Horm IGF Res.
2003;
13
185-192
-
7
Statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society .
Biochemical assessment and long-term monitoring in patients with acromegaly.
J Clin Endocrinol Metab.
2004;
89
3099-3102
-
8
Melmed S, Vance M L, Barkan A L. et al .
Current status and future opportunities for controlling acromegaly.
Pituitary.
2002;
5
185-196
-
9
Melmed S, Casanueva F F, Cavagnini F. et al .
Guidelines for acromegaly management.
J Clin Endocrinol Metab.
2002;
87
4054-4058
-
10
Trainer P J, Drake W M, Katznelson L. et al .
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
N Engl J Med.
2000;
342
1171-1177
-
11
Stewart P M.
Pegvisomant: an advance in clinical efficacy in acromegaly.
Eur J Endocrinol.
2003;
148
S27-32
(Suppl 2)
-
12
Levy M J, Matharu M S, Bhola R, Lightman S, Goadsby P J.
Somatostatin infusion withdrawal: a study of patients with migraine, cluster headache and healthy volunteers.
Pain.
2003;
102
235-241
-
13
Parkinson C, Drake W M, Roberts M E. et al .
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
J Clin Endocrinol Metab.
2002;
87
1797-1804
-
14
Trainer P J.
Metabolic effects of GH antagonism in patients with acromegaly.
Growth Horm IGF Res.
2003;
13
S152-156
(Suppl A)
-
15
Thorner M O, Strasburger C J, Wu Z. et al .
Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.
J Clin Endocrinol Metab.
1999;
84
2098-2103
Dr. med. Burkhard Herrmann
Klinik für Endokrinologie, Medizinische Klinik und Poliklinik, Zentrum für Innere Medizin, Universitätsklinikum Essen
Hufelandstraße 55
45122 Essen
Phone: 0201/7233235
Fax: 0201/7233235
